|Bid||94.55 x 6700|
|Ask||94.60 x 11200|
|Day's range||94.07 - 95.45|
|52-week range||90.00 - 115.20|
|PE ratio (TTM)||26.37|
|Earnings date||3 Aug 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.
DARMSTADT, Germany and NEW YORK , July 20, 2017 /PRNewswire/ -- Not intended for UK-based media If approved, avelumab could be the first immunotherapy treatment indicated for this ...
General Electric (GE.N), German drugmaker Merck KGaA (MRCG.DE), and Japan's Canon (7751.T) risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals. The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules. While the charges will not affect the EU approvals of the deals, they could lead to fines of up to 1 percent of global revenue for Merck KGaA and General Electric, and up to 10 percent for Canon.